Compare ALEMBIC LTD with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs PANACEA BIOTECH - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD PANACEA BIOTECH ALEMBIC LTD/
PANACEA BIOTECH
 
P/E (TTM) x 70.6 11.8 596.8% View Chart
P/BV x 2.5 2.8 88.2% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 ALEMBIC LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
PANACEA BIOTECH
Mar-18
ALEMBIC LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs72364 19.8%   
Low Rs34129 26.3%   
Sales per share (Unadj.) Rs4.796.8 4.9%  
Earnings per share (Unadj.) Rs6.1-12.4 -49.2%  
Cash flow per share (Unadj.) Rs6.2-2.9 -219.0%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.750.4 80.7%  
Shares outstanding (eoy) m267.0361.25 436.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.5 442.2%   
Avg P/E ratio x8.7-19.9 -43.7%  
P/CF ratio (eoy) x8.5-86.4 -9.8%  
Price / Book Value ratio x1.34.9 26.6%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,13915,101 93.6%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2071,516 13.7%   
Avg. sales/employee Rs ThNM2,401.9-  
Avg. wages/employee Rs ThNM614.2-  
Avg. net profit/employee Rs ThNM-307.9-  
INCOME DATA
Net Sales Rs m1,2555,928 21.2%  
Other income Rs m37082 449.8%   
Total revenues Rs m1,6256,010 27.0%   
Gross profit Rs m111845 13.1%  
Depreciation Rs m38585 6.5%   
Interest Rs m21,006 0.2%   
Profit before tax Rs m442-664 -66.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2122 57,714.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2499 24.3%   
Profit after tax Rs m1,630-760 -214.5%  
Gross profit margin %8.914.3 62.1%  
Effective tax rate %5.4-14.9 -36.5%   
Net profit margin %129.8-12.8 -1,012.8%  
BALANCE SHEET DATA
Current assets Rs m1,8675,603 33.3%   
Current liabilities Rs m5916,910 8.6%   
Net working cap to sales %101.6-22.0 -461.1%  
Current ratio x3.20.8 389.5%  
Inventory Days Days94206 45.8%  
Debtors Days Days7484 87.8%  
Net fixed assets Rs m1,7919,941 18.0%   
Share capital Rs m53461 871.3%   
"Free" reserves Rs m10,3243,026 341.2%   
Net worth Rs m10,8583,087 351.7%   
Long term debt Rs m415,707 0.7%   
Total assets Rs m11,59116,076 72.1%  
Interest coverage x260.90.3 76,656.6%   
Debt to equity ratio x01.8 0.2%  
Sales to assets ratio x0.10.4 29.4%   
Return on assets %14.11.5 920.6%  
Return on equity %15.0-24.6 -61.0%  
Return on capital %15.23.9 387.9%  
Exports to sales %1.524.0 6.4%   
Imports to sales %21.017.5 119.6%   
Exports (fob) Rs m191,424 1.4%   
Imports (cif) Rs m2631,040 25.3%   
Fx inflow Rs m191,600 1.2%   
Fx outflow Rs m2641,131 23.3%   
Net fx Rs m-244469 -52.2%   
CASH FLOW
From Operations Rs m2361,180 20.0%  
From Investments Rs m-224553 -40.5%  
From Financial Activity Rs m-27-1,644 1.6%  
Net Cashflow Rs m-1590 -16.5%  

Share Holding

Indian Promoters % 64.0 74.5 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 33.3%  
FIIs % 9.7 1.3 746.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 23.6 110.6%  
Shareholders   54,701 10,259 533.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Oct 22, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - ORCHID PHARMA LTD COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS